---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-293760"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2021-10-07T23:59:59+00:00"
generated_at: "2026-06-28T22:14:01.593297+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acumen doses first patient in Phase 1 trial of ACU193 for early Alzheimer's

## Summary
- First patient dosed in INTERCEPT-AD Phase 1 trial of ACU193 for early Alzheimer's disease.
- ACU193 is the first monoclonal antibody selectively targeting toxic amyloid-beta oligomers (AβOs).
- Trial is placebo-controlled, single- and multiple-dose; enrollment ongoing.
- CEO Daniel O'Connell: ACU193 has distinct potential to address unmet needs in Alzheimer's.

## SEC filing metadata
- accession: 0001193125-21-293760
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2021-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312521293760/0001193125-21-293760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312521293760/d208321d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-293760
- JSON: https://secwatch.observer/filing/0001193125-21-293760.json
- Plain text: https://secwatch.observer/filing/0001193125-21-293760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.